Back to search
GILD

Gilead Sciences Inc

BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) +33.6% (1Y)
Confidence Score
82%
Current Price
$122.74
Open
$123.23
Day Range
$122.38 - $123.60
Volume
3,150,184
Market Cap
$152.28B
Employees
17,600
Website
www.gilead.com

Company Description

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer the...

Analysis Summary

HIV franchise provides durable cash flows. Oncology portfolio expanding via acquisitions. 4% dividend yield with strong balance sheet.

Pro Analysis Locked

Upgrade to Pro to unlock detailed financial analysis, historical data, comparable companies, and AI-generated research reports.

Upgrade to Pro View Pricing